At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 39 enrolled
Drug / intervention
Veru-111drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Placebo-Controlled, Phase 2 Study of VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS)
In Brief
A Phase 2 clinical trial evaluating Veru-111 for Respiratory Distress Syndrome, Adult. Completed, enrolled 39 participants across 5 sites.
Detailed Summary
To demonstrate the efficacy of VERU-111 in the treatment of SARS-Cov-2 Infection by assessing its effect on the proportion of subjects that are alive without respiratory failure at Day 22. Respiratory failure is defined as non-invasive ventilation or high-flow oxygen, intubation and mechanical ventilation, or ventilation with additional organ support (e.g., pressors, RRT, ECMO).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRespiratory Distress Syndrome, Adult
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedMay 2020
Enrollment StartJun 2020
Primary CompletionDec 2020
Study CompletionAug 2021
TodayJul 2026
First PostedMay 14, 2020
Enrollment StartJun 18, 2020
Primary CompletionDec 18, 2020
Study CompletionAug 13, 2021
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 6.1 years ago
Interventions
Veru-111drug
Respiratory Distress Syndrome, Adult